Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Pancreatic Cancer News
PANCREATIC CANCER ADVISOR
Pancreatic Cancer News
Hypofractionated A-RT After Chemotherapy Resulted in Locoregional Control in Pancreatic Cancer
The single-center study evaluated 119 consecutive patients with LAPC who underwent A-RT from 2016 to 2019.
Contrast-Enhanced vs Conventional Endoscopic Ultrasound for Diagnosis of Pancreatic Lesions
A team of investigators sought to investigate the usefulness of contrast-enhanced harmonic ultrasound-guided fine needle aspiration/biopsy when performed with no on-site cytopathology.
Pegilodecakin Plus FOLFOX Fails to Improve Outcomes in Metastatic PDAC
SEQUOIA trial investigators compared pegilodecakin plus FOLFOX with FOLFOX alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Vitamin D and Pancreatic Cancer: is There a Link?
Vitamin D is a biomarker of interest in the pancreatic cancer setting.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
PERT Shows Promise in Unresected Pancreatic Cancer
Investigators compared the outcomes of patients who received pancreatic enzyme replacement therapy (PERT) with those who did not.
CD73 Inhibitor-Based Triplet Induces Responses in Metastatic PDAC
The ARC-8 study evaluated whether AB680, the anti-PD-1 antibody zimberelimab, and chemotherapy could improve metastatic pancreatic adenocarcinoma (PDAC) outcomes.
Neoadjuvant Urelumab Plus Nivolumab and GVAX for Reresected Pancreatic Cancer
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Durvalumab-Tremelimumab Plus Chemotherapy Failed to Improve Survival in Pancreatic Cancer Subtype
Durvalumab plus tremelimumab added to chemotherapy did not improve survival or response in metastatic pancreatic cancer, according to results of a phase 2 trial.
Potential Markers for High Risk of Pancreatic Cancer Identified
Using cohorts from 2 large observational studies, researchers investigated whether duration of diabetes and extent of weight loss may be a marker of risk for pancreatic cancer.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Zenocutuzumab Gets Orphan Drug Designation for Pancreatic Cancer
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
NALIRIFOX Shows Promising Anticancer Activity in Metastatic Pancreatic Ductal Adenocarcinoma
The NALIRIFOX chemotherapy regimen includes liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Neoadjuvant Treatment of Borderline-Resectable Pancreatic Cancer Led to Improved Overall Survival
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
Loading... 
Loading...